Drug intelligence / Profile preview

KJ-024-1

Development stage: Preclinical
Lead developer: Kukje Pharm

Overview

KJ-024-1 is an investigational glaucoma treatment candidate being developed by Kukje Pharmaceutical Industry. Public reporting describes it as a newly identified glaucoma-targeting candidate that was in preclinical development, with toxicology evaluation and preparation for a Phase 1 investigational new drug application reported in 2025. Its molecular modality, pharmacological target, mechanism of action, formulation, and route of administration have not been publicly disclosed. ([thebell.co.kr](https://www.thebell.co.kr/front/newsview.asp?key=202501140932407200107413))

Beyond the preview

Go deeper on KJ-024-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KJ-024-1.

Explore the full profile